Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin

focus on transporter interactions

Martha Kampp Nøhr, Sidsel Frølund, René Holm, Carsten Uhd Nielsen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Drug transporters in various tissues, such as intestine, kidney, liver and brain, are recognized as important mediators of absorption, distribution, metabolism and excretion of drug substances. This review gives a current status on the transporter(s) mediating the absorption, distribution, metabolism and excretion properties of the anti-epileptic drug substance vigabatrin. For orally administered drugs, like vigabatrin, the absorption from the intestine is a prerequisite for the bioavailability. Therefore, transporter(s) involved in the intestinal absorption of vigabatrin in vitro and in vivo are discussed in detail. Special focus is on the contribution of the proton-coupled amino acid transporter 1 (PAT1) for intestinal vigabatrin absorption. Furthermore, the review gives an overview of the pharmacokinetic parameters of vigabatrin across different species and drug-food and drug-drug interactions involving vigabatrin.

OriginalsprogEngelsk
TidsskriftTherapeutic Delivery
Vol/bind5
Udgave nummer8
Sider (fra-til)927-42
Antal sider16
ISSN2041-5990
DOI
StatusUdgivet - aug. 2014
Udgivet eksterntJa

Fingeraftryk

Vigabatrin
Pharmacokinetics
Pharmaceutical Preparations
Intestines
Drug Interactions
Protons
Kidney
Food
Liver

Citer dette

@article{661f3c000c864e879aebc6ea1ab670ba,
title = "Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin: focus on transporter interactions",
abstract = "Drug transporters in various tissues, such as intestine, kidney, liver and brain, are recognized as important mediators of absorption, distribution, metabolism and excretion of drug substances. This review gives a current status on the transporter(s) mediating the absorption, distribution, metabolism and excretion properties of the anti-epileptic drug substance vigabatrin. For orally administered drugs, like vigabatrin, the absorption from the intestine is a prerequisite for the bioavailability. Therefore, transporter(s) involved in the intestinal absorption of vigabatrin in vitro and in vivo are discussed in detail. Special focus is on the contribution of the proton-coupled amino acid transporter 1 (PAT1) for intestinal vigabatrin absorption. Furthermore, the review gives an overview of the pharmacokinetic parameters of vigabatrin across different species and drug-food and drug-drug interactions involving vigabatrin.",
author = "N{\o}hr, {Martha Kampp} and Sidsel Fr{\o}lund and Ren{\'e} Holm and Nielsen, {Carsten Uhd}",
year = "2014",
month = "8",
doi = "10.4155/tde.14.55",
language = "English",
volume = "5",
pages = "927--42",
journal = "Therapeutic Delivery",
issn = "2041-5990",
publisher = "Future Science Ltd.",
number = "8",

}

Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin : focus on transporter interactions. / Nøhr, Martha Kampp; Frølund, Sidsel; Holm, René; Nielsen, Carsten Uhd.

I: Therapeutic Delivery, Bind 5, Nr. 8, 08.2014, s. 927-42.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin

T2 - focus on transporter interactions

AU - Nøhr, Martha Kampp

AU - Frølund, Sidsel

AU - Holm, René

AU - Nielsen, Carsten Uhd

PY - 2014/8

Y1 - 2014/8

N2 - Drug transporters in various tissues, such as intestine, kidney, liver and brain, are recognized as important mediators of absorption, distribution, metabolism and excretion of drug substances. This review gives a current status on the transporter(s) mediating the absorption, distribution, metabolism and excretion properties of the anti-epileptic drug substance vigabatrin. For orally administered drugs, like vigabatrin, the absorption from the intestine is a prerequisite for the bioavailability. Therefore, transporter(s) involved in the intestinal absorption of vigabatrin in vitro and in vivo are discussed in detail. Special focus is on the contribution of the proton-coupled amino acid transporter 1 (PAT1) for intestinal vigabatrin absorption. Furthermore, the review gives an overview of the pharmacokinetic parameters of vigabatrin across different species and drug-food and drug-drug interactions involving vigabatrin.

AB - Drug transporters in various tissues, such as intestine, kidney, liver and brain, are recognized as important mediators of absorption, distribution, metabolism and excretion of drug substances. This review gives a current status on the transporter(s) mediating the absorption, distribution, metabolism and excretion properties of the anti-epileptic drug substance vigabatrin. For orally administered drugs, like vigabatrin, the absorption from the intestine is a prerequisite for the bioavailability. Therefore, transporter(s) involved in the intestinal absorption of vigabatrin in vitro and in vivo are discussed in detail. Special focus is on the contribution of the proton-coupled amino acid transporter 1 (PAT1) for intestinal vigabatrin absorption. Furthermore, the review gives an overview of the pharmacokinetic parameters of vigabatrin across different species and drug-food and drug-drug interactions involving vigabatrin.

U2 - 10.4155/tde.14.55

DO - 10.4155/tde.14.55

M3 - Journal article

VL - 5

SP - 927

EP - 942

JO - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 8

ER -